Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most general statements (IV use, hypoglycemia treatment, hyperglycemia/monitoring, hypertonicity-related local injury, need for slow infusion) align with the label for Dextrose Injection (50%) in concept, but multiple statements are either not label-supported for the specific 50% product (e.g., “D5W acts mainly as free water,” higher concentrations and complication comparisons) or are too nonspecific/conditional without label support (e.g., “depending on concentration and protocol” and “tissue injury if leaks”). Material omissions include label-specific administration constraints (central vs peripheral vein specifics, maximum infusion rate, pseudoagglutination warning, hyponatremia/avoidance details, contraindications, age restriction/almuminum toxicity).
Category Scores
Accurate Statements
Dextrose (glucose) is used clinically as an IV fluid.
Label Section 2.1/2.2: “Administer ... intravenously”
Dextrose is used to treat hypoglycemia (low blood sugar).
Label Section 1: “indicated for the treatment of insulin-induced hypoglycemia (e.g., hyperinsulinemia, insulin shock)”
IV dextrose is available in different strengths including 5% dextrose (D5W).
Label Section 3 only confirms Dextrose Injection (50%) strength; other strengths are not stated in the provided label excerpts. (Therefore this is not confidently label-supported for the specific label context.)
Common safety concerns related to IV dextrose include high blood sugar (hyperglycemia).
Label Section 5.1: hyperglycemia/hyperosmolar hyperglycemic state
IV dextrose can cause changes in fluid and electrolyte balance depending on rate and concentration.
Label Section 7.1: affects “fluid and/or electrolyte balance”
Unsupported Statements
“NPL dextrose” usually refers to a dextrose solution on an NPL (National/Non‑proprietary/Essential Medicines) list.
No NPL concept is addressed in the supplied label excerpts.
Dextrose is used to provide calories and fluids intravenously when needed.
The label provided is specific to treatment of insulin-induced hypoglycemia, not nutrition/calorie provision.
Dextrose is used for support of nutrition/hydration in certain settings depending on concentration and protocol.
Not supported by the provided label excerpts (no nutrition/hydration indication).
5% dextrose (D5W) often acts mainly as free water after dextrose is metabolized.
Not described in the supplied label excerpts.
Higher concentrations of dextrose (e.g., D10, D25, D50) are used for rapid correction of low blood sugar.
The supplied label excerpts only address Dextrose Injection (50%) dosing/administration; no label statements about D10/D25/D50 being used for “rapid correction.”
Higher concentrations of dextrose can raise blood sugar faster.
The label warns specifically about hyperglycemia from too rapid administration of Dextrose Injection (50%), not concentration-driven speed across products.
Higher-concentration dextrose may carry a higher risk of complications if given incorrectly.
The label does not support a cross-concentration risk comparison statement.
Dextrose administration may cause tissue injury if it leaks from IV access.
The label lists “extravasation” and “vein damage,” but does not explicitly describe “tissue injury” from leaking; statement is more general than label phrasing.
Reaction risks related to IV dextrose depend on the IV formulation and the patient’s underlying condition, including kidney function, diabetes, and insulin sensitivity.
The label excerpts do not mention kidney function/insulin sensitivity as determinants of reaction risk (aside from pediatric aluminum toxicity, contraindications, and monitoring).
The choice of dextrose concentration depends on the patient’s glucose level, symptoms, route, and setting.
The label excerpts provide dosing and administration for the 50% product but do not support generalized rules for choosing concentrations.
Contradictions
Important Omissions
Specific indication limitation: insulin-induced hypoglycemia (and examples) rather than generalized hypoglycemia.
Importance:
Moderate
Recommended dosing for Dextrose Injection (50%): 10 to 25 grams (20 to 50 mL) IV once, may repeat; slowly infuse; maximum infusion rate 0.5 g/kg/hour.
Importance:
High
Blood glucose measurement instruction and emergency exception (“obtain a blood glucose level… however, in an emergency, administer promptly without awaiting results”).
Importance:
Moderate
Administration safety constraints: do not administer simultaneously with blood through same infusion set (pseudoagglutination); do not administer subcutaneously or intramuscularly; discard unused portion.
Importance:
High
Central vs peripheral vein guidance: osmolarity >900 mOsm/L; when possible central; avoid peripheral in pediatric 2–11 years.
Importance:
High
Monitoring specifics for hyperglycemia/hyperosmolar state: monitor blood and urine glucose; symptoms like mental confusion/loss of consciousness; rebound hypoglycemia guidance if abruptly discontinued (give 5% or 10%).
Importance:
Moderate
Hyponatremia warning and avoidance/monitoring: avoid in patients with or at risk for hyponatremia; if use cannot be avoided, closely monitor serum sodium/chloride, fluid status, acid-base, neurologic status.
Importance:
High
Key contraindications: intracranial/intraspinal hemorrhage, severe dehydration, alcohol withdrawal, known hypersensitivity to dextrose.
Importance:
High
Drug interaction/monitoring: can affect glycemic control, vasopressin, fluid/electrolyte balance; avoid/excess risk with drugs associated with hyponatremia and monitor serum sodium.
Importance:
High
Specific population restrictions: not approved for pediatric <2 years due to aluminum toxicity; pediatric monitoring for hyponatremia/hyponatremic encephalopathy.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several high-impact label elements (dose/rate limits, central vs peripheral vein instructions, pseudoagglutination warning, hyponatremia avoidance/monitoring, contraindications, and drug interaction guidance) were omitted or not label-specific. Some generalized statements may mislead if treated as complete label guidance for Dextrose Injection (50%).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Label-specific operational details (dose/rate, administration constraints, hyponatremia monitoring/avoidance, contraindications, and drug interaction/monitoring) are largely missing or generalized beyond the provided Dextrose Injection (50%) label excerpts.
Suggested Improvement
Restrict claims to the provided indication (insulin-induced hypoglycemia) and explicitly include label-directed administration (IV only; do not co-infuse with blood; central/large peripheral vein and peripheral avoidance per age; slowly infuse with max 0.5 g/kg/hour), key warnings (hyperglycemia from rapid infusion; monitor blood/urine glucose; hyponatremia risk with avoidance/monitoring), contraindications, and interaction/monitoring with hyponatremia-associated drugs.